

Loreto Carmona

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4502831/publications.pdf>

Version: 2024-02-01

292
papers

32,055
citations

15504

65
h-index

4432

172
g-index

327
all docs

327
docs citations

327
times ranked

39673
citing authors

#	ARTICLE	IF	CITATIONS
1	Response to: "Correspondence on "Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry" by Arnaud and Devilliers. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e114-e114.	0.9	2
2	Response to: "Correspondence on "Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry" by Mulhearn <i>et al</i> . <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e116-e116.	0.9	87
3	Response to: "Correspondence on "Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry" by Rosenbaum <i>et al</i> . <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e139-e139.	0.9	2
4	Patient perspectives on long-term outcomes in rheumatoid arthritis. A qualitative study from the OMERACT patient outcomes in longitudinal studies working group. <i>Seminars in Arthritis and Rheumatism</i> , 2023, 58, 152028.	3.4	1
5	Patient's experiences of the barriers and facilitators to Methotrexate. <i>Musculoskeletal Care</i> , 2022, 20, 158-166.	1.4	6
6	SARS-CoV-2 infection after vaccination in patients with inflammatory rheumatic and musculoskeletal diseases. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 145-150.	0.9	30
7	More, none, less therapeutic effect? Should we start talking about a "lessebo" effect?. <i>Rheumatology</i> , 2022, 61, 486-487.	1.9	0
8	Intra-articular therapies: patient preferences and professional practices in European countries. <i>Rheumatology International</i> , 2022, 42, 869-878.	3.0	6
9	Multilevel factors predict medication adherence in rheumatoid arthritis: a 6-month cohort study. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 327-334.	0.9	15
10	Dietary supplements for chronic gout. <i>The Cochrane Library</i> , 2022, 2022, CD010156.	2.8	1
11	Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 695-709.	0.9	130
12	Reducing bureaucracy in clinical trials, now is the time!. <i>RMD Open</i> , 2022, 8, e002202.	3.8	2
13	Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 970-978.	0.9	49
14	SARS-CoV-2 breakthrough infections among vaccinated individuals with rheumatic disease: results from the COVID-19 Global Rheumatology Alliance provider registry. <i>RMD Open</i> , 2022, 8, e002187.	3.8	34
15	Developing guidelines for ultrarare rheumatic disorders: a bumpy ride. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1203-1205.	0.9	4
16	Development and external validation of prediction models for adverse health outcomes in rheumatoid arthritis: A multinational real-world cohort analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 56, 152050.	3.4	8
17	The journey of the non-radiographic axial spondyloarthritis patient: the perspective of professionals and patients. <i>Clinical Rheumatology</i> , 2021, 40, 591-600.	2.2	11
18	Outcomes Reported in Prospective Long-Term Observational Studies and Registries of Patients With Rheumatoid Arthritis Worldwide: An Outcome Measures in Rheumatology Systematic Review. <i>Arthritis Care and Research</i> , 2021, 73, 649-657.	3.4	6

#	ARTICLE	IF	CITATIONS
19	EULAR recommendations for the reporting of ultrasound studies in rheumatic and musculoskeletal diseases (RMDs). <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 840-847.	0.9	31
20	Development of a Tool to Measure the Clinical Response to Biologic Therapy in Uncontrolled Severe Asthma: The FEV1, Exacerbations, Oral Corticosteroids, Symptoms Score. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2725-2731.	3.8	24
21	Características epidemiológicas y eventos adversos de los pacientes con artritis psoriásica en tratamiento con terapias biológicas en Galicia. <i>Reumatología Clínica</i> , 2021, 17, 150-154.	0.5	0
22	Epidemiological characteristics and adverse events of patients with psoriatic arthritis undergoing treatment with biological therapies in Galicia. <i>Reumatología Clínica (English Edition)</i> , 2021, 17, 150-154.	0.3	0
23	Revisión sistemática del uso de metotrexato por vía parenteral en enfermedades reumáticas. <i>Reumatología Clínica</i> , 2021, , .	0.5	1
24	Adherence to subcutaneous biological therapies in patients with inflammatory rheumatic diseases and inflammatory bowel disease: a systematic review. <i>Immunotherapy</i> , 2021, 13, 433-458.	2.0	4
25	Relation of the Serum Levels of DKK-1 and Osteoprotegerin with Bone Mass in Tightly Controlled Rheumatoid Arthritis. <i>Current Rheumatology Reviews</i> , 2021, 17, 101-108.	0.8	0
26	Assessment of impact of the COVID-19 pandemic from the perspective of patients with rheumatic and musculoskeletal diseases in Europe: results from the REUMAVID study (phase 1). <i>RMD Open</i> , 2021, 7, e001546.	3.8	46
27	Prospective multicentre study of experience in real-world clinical practice in monitoring reported outcome measures (PROMs) of patient with a diagnosis of psoriatic and/or spondyloarthritis and initiating treatment with secukinumab. <i>Reumatología Clínica (English Edition)</i> , 2021, 18, 25-29.	0.3	1
28	EULAR COVID-19 registry: lessons learnt and future considerations. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1110-1115.	0.9	6
29	Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1137-1146.	0.9	151
30	Multicenter Study of Secukinumab Survival and Safety in Spondyloarthritis and Psoriatic Arthritis: SEcukinumab in Cantabria and ASTURias Study. <i>Frontiers in Medicine</i> , 2021, 8, 679009.	2.6	27
31	Disease Activity Indices in Rheumatoid Arthritis: Comparative Performance to Detect Changes in Function, IL-6 Levels, and Radiographic Progression. <i>Frontiers in Medicine</i> , 2021, 8, 669688.	2.6	2
32	2021 EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1278-1285.	0.9	124
33	Effectiveness of self-management interventions in inflammatory arthritis: a systematic review informing the 2021 EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis. <i>RMD Open</i> , 2021, 7, e001647.	3.8	21
34	EULAR recommendations for intra-articular therapies. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1299-1305.	0.9	42
35	Efficacy and safety of intra-articular therapies in rheumatic and musculoskeletal diseases: an overview of systematic reviews. <i>RMD Open</i> , 2021, 7, e001658.	3.8	15
36	Influence of prognosis factors on the prescription of targeted treatments in rheumatoid arthritis: A Delphi survey. <i>Joint Bone Spine</i> , 2021, 88, 105172.	1.6	0

#	ARTICLE	IF	CITATIONS
37	Development of a patient-centered core domain set for prospective observational longitudinal outcome studies in rheumatoid arthritis: an OMERACT initiative. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1113-1116.	3.4	4
38	Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases. <i>Lancet Rheumatology</i> , The, 2021, 3, e707-e714.	3.9	40
39	Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 930-942.	0.9	496
40	2020 EULAR points to consider for the prevention, screening, assessment and management of non-adherence to treatment in people with rheumatic and musculoskeletal diseases for use in clinical practice. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 707-713.	0.9	30
41	Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. <i>JAMA Network Open</i> , 2021, 4, e2129639.	5.9	86
42	Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study. <i>Lancet Rheumatology</i> , The, 2021, 3, e855-e864.	3.9	38
43	Aspectos prácticos de la medición de los niveles de fármacos biológicos y de anticuerpos antifármaco en artritis reumatoide y espondiloartritis. <i>Reumatología Clínica</i> , 2020, 16, 378-385.	0.5	5
44	Antisynthetase antibodies in clinical laboratories: the importance of clinical correlation and indirect immunofluorescence. Response to: Comment on: "Idiopathic inflammatory myopathies and antisynthetase syndrome: contribution of antisynthetase antibodies to improve current classification criteria" by Greco et al by Knitza et al. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e87-e87.	0.9	3
45	Satisfacción, cumplimiento de expectativas y adherencia al fármaco biológico subcutáneo en pacientes con artritis reumatoide. Estudio ARCO. <i>Reumatología Clínica</i> , 2020, 16, 116-119.	0.5	4
46	Practical aspects of biological through levels and antidrug antibodies in rheumatoid arthritis and spondyloarthritis. <i>Reumatología Clínica (English Edition)</i> , 2020, 16, 378-385.	0.3	1
47	EULAR/eumusc.net standards of care for rheumatoid arthritis: cross-sectional analyses of importance, level of implementation and care gaps experienced by patients and rheumatologists across 35 European countries. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1423-1431.	0.9	11
48	Patients' perceptions on shared decision making during prescription of subcutaneous biological drug treatments for inflammatory arthritis: The RHEUMA-LIFE survey. <i>Musculoskeletal Care</i> , 2020, 18, 568-574.	1.4	3
49	Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1544-1549.	0.9	173
50	Interobserver reliability of Masei index validation by a multicenter collaborative group of rheumatologists. <i>Rheumatology International</i> , 2020, , 1.	3.0	2
51	Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 859-866.	0.9	908
52	EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 851-858.	0.9	204
53	Satisfaction, fulfillment of expectations and adherence to subcutaneous biological drugs in patients with rheumatoid arthritis: ARCO study. <i>Reumatología Clínica (English Edition)</i> , 2020, 16, 116-119.	0.3	1
54	Effect of an abdominal hypopressive technique programme on pelvic floor muscle tone and urinary incontinence in women: a randomised crossover trial. <i>Physiotherapy</i> , 2020, 108, 37-44.	0.4	9

#	ARTICLE	IF	CITATIONS
55	Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries. <i>Lancet Rheumatology</i> , The, 2020, 2, e250-e253.	3.9	172
56	Prevention, screening, assessing and managing of non-adherent behaviour in people with rheumatic and musculoskeletal diseases: systematic reviews informing the 2020 EULAR points to consider. <i>RMD Open</i> , 2020, 6, e001432.	3.8	23
57	2018 update of the EULAR recommendations for the management of hand osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 16-24.	0.9	273
58	Measuring inflammation in rheumatoid arthritis with a new clinical and ultrasound index: development and initial validation. <i>Rheumatology International</i> , 2019, 39, 2137-2145.	3.0	2
59	Facing arthritis: helping patients to handle their disease and concerns. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 903-905.	3.0	2
60	Meta-analysis in the era of big data. <i>Clinical Rheumatology</i> , 2019, 38, 2027-2028.	2.2	6
61	Launch and Preliminary Analysis of Hospital de La Princesa's Inter-specialists Biological Therapies Unit. <i>Reumatología Clínica (English Edition)</i> , 2019, 15, 63-68.	0.3	0
62	Discordance between doctor and patient assessments and non-adherence to subcutaneous biological drugs. <i>Rheumatology International</i> , 2019, 39, 1077-1082.	3.0	4
63	Core Outcome Sets Specifically for Longterm Observational Studies: OMERACT Special Interest Group Update in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2019, 46, 1164-1167.	2.0	7
64	Idiopathic inflammatory myopathies and antisynthetase syndrome: contribution of antisynthetase antibodies to improve current classification criteria. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1291-1292.	0.9	16
65	The comparative responsiveness of Hospital Universitario Princesa Index and other composite indices for assessing rheumatoid arthritis activity. <i>PLoS ONE</i> , 2019, 14, e0214717.	2.5	2
66	Launch and preliminary analysis of Hospital de La Princesa's inter-specialists biological therapies unit. <i>Reumatología Clínica</i> , 2019, 15, 63-68.	0.5	1
67	The epidemiology of established rheumatoid arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2019, 33, 101477.	3.3	81
68	EULAR points to consider for the development, evaluation and implementation of mobile health applications aiding self-management in people living with rheumatic and musculoskeletal diseases. <i>RMD Open</i> , 2019, 5, e001014.	3.8	73
69	Failure to reach uric acid target of $\leq 0.36\text{ mmol/L}$ in hyperuricaemia of gout is associated with elevated total and cardiovascular mortality. <i>RMD Open</i> , 2019, 5, e001015.	3.8	49
70	Perceptions of Patients With Rheumatic Diseases Treated With Subcutaneous Biologicals on Their Level of Information: RHEU-LIFE Survey. <i>Reumatología Clínica (English Edition)</i> , 2019, 15, 343-349.	0.3	2
71	Severity Indices in Rheumatoid Arthritis: A Systematic Review. <i>Reumatología Clínica (English Edition)</i> , 2019, 15, 146-151.	0.3	2
72	Recommendations for the Prescription of Physical Exercise for Patients With Spondyloarthritis. <i>Reumatología Clínica (English Edition)</i> , 2019, 15, 77-83.	0.3	2

#	ARTICLE	IF	CITATIONS
73	Recomendaciones para la prescripción de ejercicio físico en pacientes con espondiloartritis. <i>Reumatología Clínica</i> , 2019, 15, 77-83.	0.5	9
74	Índices de gravedad en la artritis reumatoide: una revisión sistemática. <i>Reumatología Clínica</i> , 2019, 15, 146-151.	0.5	1
75	Percepciones de los pacientes con enfermedades reumáticas tratados con biológicos subcutáneos sobre su nivel de información. Encuesta RHEU-LIFE. <i>Reumatología Clínica</i> , 2019, 15, 343-349.	0.5	2
76	Serum drug levels of biologic agents in the management of rheumatoid arthritis and spondyloarthritis: a systematic review. <i>Rheumatology International</i> , 2018, 38, 975-983.	3.0	15
77	The population impact of rheumatic and musculoskeletal diseases in relation to other non-communicable disorders: comparing two estimation approaches. <i>Rheumatology International</i> , 2018, 38, 905-915.	3.0	10
78	Prevalence and risk factors for osteoporosis and fractures in axial spondyloarthritis: A systematic review and meta-analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 44-52.	3.4	53
79	2017 EULAR recommendations for a core data set to support observational research and clinical care in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 476-479.	0.9	47
80	Weather conditions and their effect on seasonality of incident osteoporotic hip fracture. <i>Archives of Osteoporosis</i> , 2018, 13, 28.	2.4	29
81	Recomendaciones para el manejo de la comorbilidad en la práctica clínica en pacientes con espondiloartritis axial. <i>Reumatología Clínica</i> , 2018, 14, 346-359.	0.5	7
82	2013 ACR/EULAR systemic sclerosis classification criteria in patients with associated pulmonary arterial hypertension. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 870-876.	3.4	7
83	Second Hip Fracture: Incidence, Trends, and Predictors. <i>Calcified Tissue International</i> , 2018, 102, 619-626.	3.1	18
84	Efficacy and safety of non-pharmacological, pharmacological and surgical treatment for hand osteoarthritis: a systematic literature review informing the 2018 update of the EULAR recommendations for the management of hand osteoarthritis. <i>RMD Open</i> , 2018, 4, e000734.	3.8	71
85	Overview of changes in RMD epidemiology and outcome development in the last 10 years. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018, 32, 169-173.	3.3	3
86	Epidemiology of rheumatic and musculoskeletal diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018, 32, 167-168.	3.3	4
87	Use of prognostic factors of rheumatoid arthritis in clinical practice and perception of their predictive capacity before and after exposure to evidence. <i>Rheumatology International</i> , 2018, 38, 2289-2296.	3.0	6
88	Recommendations for the Management of Comorbidity in Patients With Axial Spondyloarthritis in Clinical Practice. <i>Reumatología Clínica (English Edition)</i> , 2018, 14, 346-359.	0.3	1
89	The EJES-3D tool for personalized prescription of exercise in axial spondyloarthritis through multimedia animations: pilot study. <i>Rheumatology International</i> , 2018, 38, 1277-1284.	3.0	2
90	Effect of Weight Loss on Activity in Psoriatic Arthritis: A Systematic Review. <i>Reumatología Clínica (English Edition)</i> , 2018, 14, 207-210.	0.3	6

#	ARTICLE	IF	CITATIONS
91	The beliefs of rheumatoid arthritis patients in their subcutaneous biological drug: strengths and areas of concern. <i>Rheumatology International</i> , 2018, 38, 1735-1740.	3.0	3
92	High Reproducibility of an Automated Measurement of Mobility for Patients with Axial Spondyloarthritis. <i>Journal of Rheumatology</i> , 2018, 45, 1383-1388.	2.0	6
93	Ensuring the Consistency of Biosimilars. <i>Current Pharmaceutical Design</i> , 2018, 23, 6733-6738.	1.9	4
94	Are rheumatologists adhering to the concepts window of opportunity and treat-to-target? Earlier and more intense disease-modifying anti-rheumatic drug treatment over time in patients with early arthritis in the PEARL study. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 382-388.	0.8	12
95	Barreras y facilitadores para la prÁctica del ejercicio fÁsico en pacientes con espondiloartritis: estudio cualitativo de grupos focales (EJES-3D). <i>ReumatologÁa ClÁnica</i> , 2017, 13, 91-96.	0.5	10
96	Disease Activity As a Major Determinant of Quality of Life and Physical Function in Patients With Early Axial Spondyloarthritis. <i>Arthritis Care and Research</i> , 2017, 69, 150-155.	3.4	22
97	Diagnostic Value and Validity of Early Spondyloarthritis Features: Results From a National Spanish Cohort. <i>Arthritis Care and Research</i> , 2017, 69, 938-942.	3.4	10
98	Cardiovascular risk of patients with gout seen at rheumatology clinics following a structured assessment. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1263-1268.	0.9	38
99	Economic considerations and patients' preferences affect treatment selection for patients with rheumatoid arthritis: a discrete choice experiment among European rheumatologists. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 126-132.	0.9	33
100	EULAR/PReS standards and recommendations for the transitional care of young people with juvenile-onset rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 639-646.	0.9	157
101	Identification and management of comorbidity in psoriatic arthritis: evidence- and expert-based recommendations from a multidisciplinary panel from Spain. <i>Rheumatology International</i> , 2017, 37, 1239-1248.	3.0	24
102	The challenge of the definition of early symptomatic knee osteoarthritis: a proposal of criteria and red flags from an international initiative promoted by the Italian Society for Rheumatology. <i>Rheumatology International</i> , 2017, 37, 1227-1236.	3.0	22
103	Critical Outcomes in Longitudinal Observational Studies and Registries in Patients with Rheumatoid Arthritis: An OMERACT Special Interest Group Report. <i>Journal of Rheumatology</i> , 2017, 44, 1894-1898.	2.0	12
104	Identification of patients at risk of non-adherence to oral antirheumatic drugs in rheumatoid arthritis using the Compliance Questionnaire in Rheumatology: an ARCO sub-study. <i>Rheumatology International</i> , 2017, 37, 1195-1202.	3.0	27
105	Early Mortality in a Multinational Systemic Sclerosis Inception Cohort. <i>Arthritis and Rheumatology</i> , 2017, 69, 1067-1077.	5.6	139
106	Trends in osteoporotic hip fracture epidemiology over a 17-year period in a Spanish population: AlcorcÁn 1999â€“2015. <i>Archives of Osteoporosis</i> , 2017, 12, 84.	2.4	19
107	Restless farewell. <i>Rheumatology International</i> , 2017, 37, 1601-1602.	3.0	1
108	Patientâ€“physician collaboration in rheumatology: a necessity. <i>RMD Open</i> , 2017, 3, e000499.	3.8	14

#	ARTICLE	IF	CITATIONS
109	Management of the Psychological Impact of Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2017, 23, 1492-1498.	1.9	27
110	The 2017 EULAR standardised procedures for ultrasound imaging in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1974-1979.	0.9	191
111	Transitional care for rheumatic conditions in Europe: current clinical practice and available resources. <i>Pediatric Rheumatology</i> , 2017, 15, 49.	2.1	39
112	Systematic review of systemic sclerosis-specific instruments for the EULAR Outcome Measures Library: An evolutionary database model of validated patient-reported outcomes. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 46, 609-614.	3.4	16
113	Efficacy and safety of home-based exercises versus individualized supervised outpatient physical therapy programs after total knee arthroplasty: a systematic review and meta-analysis. <i>Knee Surgery, Sports Traumatology, Arthroscopy</i> , 2017, 25, 3340-3353.	4.2	42
114	Patterns and Consequences of Multimorbidity in the General Population: There is No Chronic Disease Management Without Rheumatic Disease Management. <i>Arthritis Care and Research</i> , 2017, 69, 12-20.	3.4	36
115	Perceptions of patients with rheumatic diseases on the impact on daily life and satisfaction with their medications: RHEU-LIFE, a survey to patients treated with subcutaneous biological products. <i>Patient Preference and Adherence</i> , 2017, Volume 11, 1243-1252.	1.8	22
116	The Challenge of Assessing Adherence to Subcutaneous Biological Drugs in Immune-Mediated Inflammatory Diseases. Letter to the Editor Regarding Michetti P, Weinman J, Mrowietz U, et al. <i>Adv Ther</i> (2017);34:91-108. doi:10.1007/s12325-016-0441-3. <i>Advances in Therapy</i> , 2017, 34, 2173-2176.	2.9	8
117	Weight loss for overweight and obese individuals with gout: a systematic review of longitudinal studies. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1870-1882.	0.9	98
118	Non-adherence to subcutaneous biological medication in patients with rheumatoid arthritis: a multicentre, non-interventional study. <i>Clinical and Experimental Rheumatology</i> , 2017, 35, 423-430.	0.8	22
119	Effect of Osteoprotegerin and Dickkopf-Related Protein 1 on Radiological Progression in Tightly Controlled Rheumatoid Arthritis. <i>PLoS ONE</i> , 2016, 11, e0166691.	2.5	8
120	Epidemiology and health-related services. <i>Current Opinion in Rheumatology</i> , 2016, 28, 104-109.	4.3	2
121	Points to consider for reporting, screening for and preventing selected comorbidities in chronic inflammatory rheumatic diseases in daily practice: a EULAR initiative. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 965-973.	0.9	179
122	Prevalence of rheumatic and musculoskeletal diseases and their impact on health-related quality of life, physical function and mental health in Portugal: results from EpiReumaPt – a national health survey. <i>RMD Open</i> , 2016, 2, e000166.	3.8	133
123	Is Obesity in Psoriatic Arthritis Associated With a Poorer Therapeutic Response and More Adverse Effects of Treatment With an Anchor Drug?. <i>Reumatologia Clínica (English Edition)</i> , 2016, 12, 307-312.	0.3	11
124	Consensus Statement on the Management of Comorbidity in Patients with Rheumatoid Arthritis and Psoriasis. <i>Journal of Rheumatology</i> , 2016, 43, 990-991.	2.0	3
125	Centre-related variability in hospital admissions of patients with spondyloarthritis. <i>Rheumatology International</i> , 2016, 36, 1301-1308.	3.0	0
126	Systematic review and critical appraisal of transitional care programmes in rheumatology. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, 372-379.	3.4	58

#	ARTICLE	IF	CITATIONS
127	Centre characteristics determine ambulatory care and referrals in patients with spondyloarthritis. <i>Rheumatology International</i> , 2016, 36, 1515-1523.	3.0	1
128	PROMs for Fibromyalgia. , 2016, , 175-208.		1
129	Validation of the 2013 American College of Rheumatology/European League Against Rheumatism classification criteria for systemic sclerosis in patients from a capillaroscopy clinic. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, 350-355.	3.4	10
130	EULAR recommendations for the management of familial Mediterranean fever. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 644-651.	0.9	393
131	¿Se asocia la obesidad en la artritis psoriásica a una menor respuesta terapéutica y más efectos adversos con el tratamiento de fondo?. <i>Reumatología Clínica</i> , 2016, 12, 307-312.	0.5	27
132	Cut-Offs and Response Criteria for the Hospital Universitario La Princesa Index (HUPI) and Their Comparison to Widely-Used Indices of Disease Activity in Rheumatoid Arthritis. <i>PLoS ONE</i> , 2016, 11, e0161727.	2.5	11
133	Incidence of Physical Disability Related to Musculoskeletal Disorders in the Elderly: Results From a Primary Care-Based Registry. <i>Arthritis Care and Research</i> , 2015, 67, 89-93.	3.4	8
134	The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers. <i>Rheumatology</i> , 2015, 54, 1074-1079.	1.9	22
135	Is Spinal Mobility in Patients With Spondylitis Determined By Age, Structural Damage, and Inflammation?. <i>Arthritis Care and Research</i> , 2015, 67, 74-79.	3.4	29
136	2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 8-13.	0.9	223
137	High Sodium Intake Is Associated With Self-Reported Rheumatoid Arthritis. <i>Medicine (United States)</i> , 2015, 94, e0924.	1.0	64
138	Recomendaciones para la detección, investigación y derivación del dolor lumbar inflamatorio en Atención Primaria. <i>Reumatología Clínica</i> , 2015, 11, 90-98.	0.5	13
139	Predictors of treatment failure and mortality in native septic arthritis. <i>Clinical Rheumatology</i> , 2015, 34, 1961-1967.	2.2	38
140	Consensus statement on a framework for the management of comorbidity and extra-articular manifestations in rheumatoid arthritis. <i>Rheumatology International</i> , 2015, 35, 445-458.	3.0	46
141	Recommendations for the Detection, Study and Referral of Inflammatory Low-back Pain in Primary Care. <i>Reumatología Clínica (English Edition)</i> , 2015, 11, 90-98.	0.3	5
142	An early intervention program for subacute physical disability related to musculoskeletal diseases in the elderly: a pilot study. <i>Rheumatology International</i> , 2015, 35, 1183-1191.	3.0	1
143	Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 963-969.	0.9	36
144	Primary prophylaxis to prevent obstetric complications in asymptomatic women with antiphospholipid antibodies: a systematic review. <i>Lupus</i> , 2015, 24, 1135-1142.	1.6	48

#	ARTICLE	IF	CITATIONS
145	Consensus of the Spanish society of pediatric rheumatology for transition management from pediatric to adult care in rheumatic patients with childhood onset. <i>Rheumatology International</i> , 2015, 35, 1615-1624.	3.0	28
146	The accuracy of osteoporotic fracture risk prediction tools: a systematic review and meta-analysis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1958-1967.	0.9	128
147	Safety of allopurinol compared with other urate-lowering drugs in patients with gout: a systematic review and meta-analysis. <i>Rheumatology International</i> , 2015, 35, 1127-1137.	3.0	28
148	Lipid Profile Changes in Patients With Chronic Inflammatory Arthritis Treated With Biologic Agents and Tofacitinib in Randomized Clinical Trials: A Systematic Review and Meta-analysis. <i>Arthritis and Rheumatology</i> , 2015, 67, 117-127.	5.6	125
149	The EULAR Outcome Measures Library: an evolutionary database of validated patient-reported instruments. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 475-476.	0.9	26
150	Development of patient-centred standards of care for osteoarthritis in Europe: the eumusc.net-project. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1145-1149.	0.9	68
151	Adherence to biologic therapies and associated factors in rheumatoid arthritis, spondyloarthritis and psoriatic arthritis: a systematic literature review. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 559-69.	0.8	31
152	EpiReumaPt- the study of rheumatic and musculoskeletal diseases in Portugal: a detailed view of the methodology. <i>Acta Reumatológica Portuguesa</i> , 2015, 40, 110-24.	0.2	26
153	Treatment Target and Followup Measures for Patients with Gout: A Systematic Literature Review. <i>Journal of rheumatology Supplement</i> , The, 2014, 92, 55-62.	2.2	7
154	Dietary supplements for chronic gout. <i>The Cochrane Library</i> , 2014, , CD010156.	2.8	18
155	Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies. <i>Rheumatology</i> , 2014, 53, 1872-1885.	1.9	132
156	Interleukin-1 inhibitors for acute gout. <i>The Cochrane Library</i> , 2014, 2014, CD009993.	2.8	23
157	The burden of disease in Spain: results from the global burden of disease study 2010. <i>BMC Medicine</i> , 2014, 12, 236.	5.5	27
158	Is there a best way to measure co-morbidity?. <i>Rheumatology</i> , 2014, 53, 963-964.	1.9	4
159	Bone mineral density status and frequency of osteoporosis and clinical fractures in 155 patients with psoriatic arthritis followed in a university hospital. <i>Reumatología Clínica</i> , 2014, 10, 89-93.	0.5	33
160	Documento práctico para el uso de abatacept subcutáneo. <i>Reumatología Clínica</i> , 2014, 10, 218-226.	0.5	2
161	Rheumatoid factor and response to TNF antagonists in rheumatoid arthritis: Systematic review and meta-analysis of observational studies. <i>Joint Bone Spine</i> , 2014, 81, 41-50.	1.6	22
162	Observational study of optimization of biologic therapies in rheumatoid arthritis: a single-centre experience. <i>Rheumatology International</i> , 2014, 34, 1059-1063.	3.0	19

#	ARTICLE	IF	CITATIONS
163	Serious infections in patients with rheumatoid arthritis and other immune-mediated connective tissue diseases exposed to anti-TNF or rituximab: data from the Spanish registry BIOBADASER 2.0. <i>Rheumatology International</i> , 2014, 34, 953-961.	3.0	50
164	Validation of a new objective index to measure spinal mobility: the University of Cordoba Ankylosing Spondylitis Metrology Index (UCOASMI). <i>Rheumatology International</i> , 2014, 34, 401-406.	3.0	18
165	Databases and registers: useful tools for research, no studies. <i>Rheumatology International</i> , 2014, 34, 447-452.	3.0	10
166	Performance of the Assessment of Spondyloarthritis International Society criteria for the classification of spondyloarthritis in early spondyloarthritis clinics participating in the ESPERANZA programme. <i>Rheumatology</i> , 2014, 53, 353-360.	1.9	35
167	Safety profile of protein kinase inhibitors in rheumatoid arthritis: systematic review and meta-analysis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 871-882.	0.9	49
168	The Efficacy and Safety of Treatments for Acute Gout: Results from a Series of Systematic Literature Reviews Including Cochrane Reviews on Intraarticular Glucocorticoids, Colchicine, Nonsteroidal Antiinflammatory Drugs, and Interleukin-1 Inhibitors. <i>Journal of rheumatology Supplement</i> , The, 2014, 92, 15-25.	2.2	29
169	Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 177-182.	0.9	170
170	Diagnostic Value of Clinical, Laboratory, and Imaging Findings in Patients with a Clinical Suspicion of Gout: A Systematic Literature Review. <i>Journal of rheumatology Supplement</i> , The, 2014, 92, 3-8.	2.2	16
171	Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 328-335.	0.9	222
172	Clinical Composite Measures of Disease Activity and Damage Used to Evaluate Patients With Systemic Lupus Erythematosus: A Systematic Literature Review. <i>ReumatologĀa ClĀnica (English Edition)</i> , 2014, 10, 309-320.	0.3	2
173	Development of patient-centred standards of care for rheumatoid arthritis in Europe: the eumusc.net project. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 902-905.	0.9	82
174	Āndices compuestos para evaluar la actividad de la enfermedad y el da±o estructural en pacientes con lupus eritematoso: revisi3n sistemĀtica de la literatura. <i>ReumatologĀa ClĀnica</i> , 2014, 10, 309-320.	0.5	13
175	Validity of the Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients with early spondyloarthritis from the Esperanza programme. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1350-1355.	0.9	46
176	Facilitators to implement standards of care for rheumatoid arthritis and osteoarthritis: the EUMUSC.NET project. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1545-1548.	0.9	9
177	Practice Guidelines for the Use of Subcutaneous Abatacept. <i>ReumatologĀa ClĀnica (English Edition)</i> , 2014, 10, 218-226.	0.3	2
178	The global burden of rheumatoid arthritis: estimates from the Global Burden of Disease 2010 study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1316-1322.	0.9	820
179	Predicting Toxicity: Biomarkers and the Value of the Patient's Opinion. <i>Current Pharmaceutical Design</i> , 2014, 21, 233-240.	1.9	0
180	Reducing the Need for Central Dual-Energy X-Ray Absorptiometry in Postmenopausal Women: Efficacy of a Clinical Algorithm Including Peripheral Densitometry. <i>Calcified Tissue International</i> , 2013, 93, 62-68.	3.1	3

#	ARTICLE	IF	CITATIONS
181	Quality-of-care standards for early arthritis clinics. <i>Rheumatology International</i> , 2013, 33, 2459-2472.	3.0	6
182	A full new enthusiastic team. <i>Rheumatology International</i> , 2013, 33, 825-826.	3.0	2
183	Denosumab for the treatment of osteoporosis: A systematic literature review. <i>Reumatología Clínica</i> , 2013, 9, 42-52.	0.5	35
184	Factores motivadores y barreras para implantar una vÃa clÃnica de atenciÃn precoz de espondiloartritis: estudio cualitativo con mÃdicos de atenciÃn primaria. <i>Reumatología Clínica</i> , 2013, 9, 85-89.	0.5	8
185	El uso de abatacept en artritis reumatoide: revisiÃn de la evidencia y recomendaciones. <i>Reumatología Clínica</i> , 2013, 9, 5-17.	0.5	18
186	Weather conditions may worsen symptoms in rheumatoid arthritis patients: The possible effect of temperature. <i>Reumatología Clínica (English Edition)</i> , 2013, 9, 226-228.	0.3	6
187	Diferente expresiÃn clÃnica de los pacientes con espondilitis anquilosante segÃn el sexo en funciÃn del tiempo de evoluciÃn. Datos de REGISPONSER. <i>Reumatología Clínica</i> , 2013, 9, 221-225.	0.5	23
188	Denosumab for the treatment of osteoporosis: A systematic literature review. <i>Reumatología Clínica (English Edition)</i> , 2013, 9, 42-52.	0.3	4
189	Le facteur rhumatoÃde ne semble pas prÃdire la rÃponse aux anti-TNF Â dans la polyarthrite rhumatoÃde: expÃrience de trois centres. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2013, 80, 527-528.	0.0	1
190	Rheumatoid factor does not predict response to TNF antagonists in rheumatoid arthritis: Three centers experience. <i>Joint Bone Spine</i> , 2013, 80, 438-440.	1.6	4
191	Motivations and Objections to Implement a Spondyloarthritis Integrated Care Pathway. A Qualitative Study With Primary Care Physicians. <i>Reumatología Clínica (English Edition)</i> , 2013, 9, 85-89.	0.3	2
192	Weather conditions may worsen symptoms in rheumatoid arthritis patients: The possible effect of temperature. <i>Reumatología Clínica</i> , 2013, 9, 226-228.	0.5	27
193	Rheumatoid factor as predictor of response to abatacept, rituximab and tocilizumab in rheumatoid arthritis: Systematic review and meta-analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2013, 43, 9-17.	3.4	76
194	Development and Validation of a New Disease Activity Index as a Numerical Sum of Four Variables in Patients With Early Arthritis. <i>Arthritis Care and Research</i> , 2013, 65, 518-525.	3.4	11
195	Abatacept Use in Rheumatoid Arthritis: Evidence Review and Recommendations. <i>Reumatología Clínica (English Edition)</i> , 2013, 9, 5-17.	0.3	6
196	A10.24â€...Switching Infliximab for New Alternatives: A Correspondence Analysis of Biologics, Reasons to Stop, and Time Periods. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A80.3-A81.	0.9	2
197	Tackling missing radiographic progression data: multiple imputation technique compared with inverse probability weights and complete case analysis. <i>Rheumatology</i> , 2013, 52, 331-336.	1.9	6
198	Cutaneous Adverse Events During Treatment of Chronic Inflammatory Rheumatic Conditions With Tumor Necrosis Factor Antagonists: Study Using the Spanish Registry of Adverse Events of Biological Therapies in Rheumatic Diseases. <i>Arthritis Care and Research</i> , 2013, 65, 2024-2031.	3.4	52

#	ARTICLE	IF	CITATIONS
199	Orthopedic Surgery in Rheumatoid Arthritis in the Era of Biologic Therapy. <i>Journal of Rheumatology</i> , 2013, 40, 1850-1855.	2.0	23
200	Scoring with the Berlin MRI method for assessment of spinal inflammatory activity in patients with ankylosing spondylitis: a calibration exercise among rheumatologists. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, 883-8.	0.8	3
201	Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. <i>Lancet</i> , 2012, 380, 2197-2223.	13.7	7,061
202	Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. <i>Lancet</i> , 2012, 380, 2163-2196.	13.7	6,376
203	Change in the discontinuation pattern of tumour necrosis factor antagonists in rheumatoid arthritis over 10 years: data from the Spanish registry BIOBADASER 2.0. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 382-385.	0.9	61
204	Variabilidad en el consumo de recursos en pacientes con espondiloartritis en España. Datos descriptivos preliminares del estudio emAR II. <i>Reumatología Clínica</i> , 2012, 8, 114-9.	0.5	13
205	Variability in Resource Consumption in Patients With Spondyloarthritis in Spain. Preliminary Descriptive Data From the emAR II Study. <i>Reumatología Clínica (English Edition)</i> , 2012, 8, 114-119.	0.3	8
206	A meta-analysis of mortality in rheumatic diseases. <i>Reumatología Clínica (English Edition)</i> , 2012, 8, 334-341.	0.3	1
207	Management of Rheumatoid Arthritis in Spain (emAR II). Clinical Characteristics of the Patients. <i>Reumatología Clínica (English Edition)</i> , 2012, 8, 236-242.	0.3	5
208	Efficacy and Safety of TNF Antagonists in Sarcoidosis: Data from the Spanish Registry of Biologics BIOBADASER and a Systematic Review. <i>Seminars in Arthritis and Rheumatism</i> , 2012, 42, 89-103.	3.4	59
209	A meta-analysis of mortality in rheumatic diseases. <i>Reumatología Clínica</i> , 2012, 8, 334-341.	0.5	61
210	Estudio sobre el manejo de la artritis reumatoide en España (emAR II). Características clínicas de los pacientes. <i>Reumatología Clínica</i> , 2012, 8, 236-242.	0.5	15
211	Prognostic factors for long-term work disability due to musculoskeletal disorders. <i>Rheumatology International</i> , 2012, 32, 3831-3839.	3.0	20
212	Effectiveness of a clinical practice intervention in early rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2012, 64, 321-330.	3.4	17
213	The practical value of biologics registries in Africa and Middle East: challenges and opportunities. <i>Clinical Rheumatology</i> , 2012, 31, 407-416.	2.2	7
214	Infections in Patients with Rheumatic Diseases Treated with TNF Antagonists. <i>Current Pharmaceutical Biotechnology</i> , 2012, 13, 1418-1425.	1.6	6
215	Prevalence of Vertebral Fractures by Semiautomated Morphometry in Patients with Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2011, 38, 893-897.	2.0	57
216	Systematic review: Safety and efficacy of anti-TNF in elderly patients. <i>Reumatología Clínica (English)</i>	0.3	7

#	ARTICLE	IF	CITATIONS
217	Characteristics of early arthritis units that may be associated with better referral efficiency: survey of SERAP units. <i>Reumatología Clínica (English Edition)</i> , 2011, 7, 236-240.	0.3	3
218	Consensus Statement of the Spanish Society of Rheumatology on Risk Management of Biologic Therapy in Rheumatic Patients. <i>Reumatología Clínica (English Edition)</i> , 2011, 7, 284-298.	0.3	21
219	Infections in patients treated with tumor necrosis factor antagonists: incidence, etiology and mortality in the BIOBADASER registry. <i>Medicina Clínica</i> , 2011, 137, 533-540.	0.6	72
220	An Audit of the Variability of Diagnosis and Management of Gout in the Rheumatology Setting. <i>Journal of Clinical Rheumatology</i> , 2011, 17, 349-355.	0.9	41
221	Systematic Review on the Effectiveness of Immunosuppressants and Biological Therapies in the Treatment of Autoimmune Posterior Uveitis. <i>Seminars in Arthritis and Rheumatism</i> , 2011, 40, 314-323.	3.4	76
222	Demyelinating Disease in Patients Treated with TNF Antagonists in Rheumatology: Data from BIOBADASER, a Pharmacovigilance Database, and a Systematic Review. <i>Seminars in Arthritis and Rheumatism</i> , 2011, 40, 330-337.	3.4	49
223	Cancer in Patients with Rheumatic Diseases Exposed to TNF Antagonists. <i>Seminars in Arthritis and Rheumatism</i> , 2011, 41, 71-80.	3.4	94
224	Demyelinating Disease in Patients Treated with TNF Antagonists in Rheumatology: Data from BIOBADASER, a Pharmacovigilance Database, and a Systematic Review. <i>Seminars in Arthritis and Rheumatism</i> , 2011, 41, 524-533.	3.4	60
225	Development of quality indicators to evaluate the monitoring of SLE patients in routine clinical practice. <i>Autoimmunity Reviews</i> , 2011, 10, 383-388.	5.8	71
226	A two-stage approach to the treatment of hyperuricemia in gout: The "dirty dish" hypothesis. <i>Arthritis and Rheumatism</i> , 2011, 63, 4002-4006.	6.7	67
227	A model for the development and implementation of a national plan for the optimal management of early spondyloarthritis: the Esperanza Program. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 827-830.	0.9	37
228	Algorithm for Identification of Undifferentiated Peripheral Inflammatory Arthritis: A Multinational Collaboration Through the 3e Initiative. <i>Journal of rheumatology Supplement, The</i> , 2011, 87, 54-58.	2.2	11
229	Clinical Composite Measures of Disease Activity for Diagnosis and Followup of Undifferentiated Peripheral Inflammatory Arthritis: A Systematic Review. <i>Journal of rheumatology Supplement, The</i> , 2011, 87, 48-53.	2.2	3
230	Age at treatment predicts reason for discontinuation of TNF antagonists: data from the BIOBADASER 2.0 registry. <i>Rheumatology</i> , 2011, 50, 1999-2004.	1.9	44
231	Safety and retention rate of off-label uses of TNF antagonists in rheumatic conditions: data from the Spanish registry BIOBADASER 2.0. <i>Rheumatology</i> , 2011, 50, 85-92.	1.9	36
232	Multinational evidence-based recommendations on how to investigate and follow-up undifferentiated peripheral inflammatory arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 15-24.	0.9	68
233	Diagnostic and Prognostic Value of Genetics in Undifferentiated Peripheral Inflammatory Arthritis: A Systematic Review. <i>Journal of rheumatology Supplement, The</i> , 2011, 87, 38-44.	2.2	2
234	Finalisation and validation of the rheumatoid arthritis impact of disease score, a patient-derived composite measure of impact of rheumatoid arthritis: a EULAR initiative. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 935-942.	0.9	238

#	ARTICLE	IF	CITATIONS
235	Survival, Causes of Death, and Risk Factors Associated With Mortality in Spanish Systemic Sclerosis Patients: Results From a Single University Hospital. <i>Seminars in Arthritis and Rheumatism</i> , 2010, 39, 285-293.	3.4	62
236	A Comparison of Patient Characteristics and Outcomes in Selected European and U.S. Rheumatoid Arthritis Registries. <i>Seminars in Arthritis and Rheumatism</i> , 2010, 40, 2-14.e1.	3.4	161
237	Rheumatoid arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2010, 24, 733-745.	3.3	183
238	Limited value of ultrasound assessment in patients with poor outcome after carpal tunnel release surgery. <i>Scandinavian Journal of Rheumatology</i> , 2010, 39, 409-412.	1.1	42
239	Incidence and risk of hospitalisation due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1751-1755.	0.9	96
240	European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1269-1274.	0.9	308
241	Anti-TNF therapy and cancer. <i>Reumatología Clínica (English Edition)</i> , 2010, 6, 102-105.	0.3	3
242	Biobadaser 2.0: analysis and trends in 2009. <i>Reumatología Clínica (English Edition)</i> , 2010, 6, 240-243.	0.3	3
243	The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement. <i>European Respiratory Journal</i> , 2010, 36, 1185-1206.	6.7	444
244	EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1596-1602.	0.9	87
245	Assessment of multiple organ systems in systemic lupus erythematosus: what will the new guidelines mean?. <i>International Journal of Clinical Rheumatology</i> , 2010, 5, 291-297.	0.3	2
246	Despair on disparities. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 1657-1658.	0.9	4
247	Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 1086-1093.	0.9	404
248	Multimorbidity: Prevalence, Effect on Quality of Life and Daily Functioning, and Variation of This Effect When one Condition Is a Rheumatic Disease. <i>Seminars in Arthritis and Rheumatism</i> , 2009, 38, 312-319.	3.4	124
249	Economic burden of knee and hip osteoarthritis in Spain. <i>Arthritis and Rheumatism</i> , 2009, 61, 158-165.	6.7	109
250	Elaboration of the preliminary Rheumatoid Arthritis Impact of Disease (RAID) score: a EULAR initiative. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 1680-1685.	0.9	190
251	Pattern of use and safety of non-steroidal anti-inflammatory drugs in rheumatoid arthritis patients. A prospective analysis from clinical practice. <i>Reumatología Clínica (English Edition)</i> , 2009, 5, 252-258.	0.5	13
252	Characteristics of Paget's disease in Spain. Data from the National Paget's Register. <i>Reumatología Clínica (English Edition)</i> , 2009, 5, 109-114.	0.3	0

#	ARTICLE	IF	CITATIONS
253	What are patients with early rheumatoid arthritis like in Spain? Description of the PROAR cohort. <i>Reumatología Clínica (English Edition)</i> , 2009, 5, 115-120.	0.3	2
254	Prognostic factors in short-term disability due to musculoskeletal disorders. <i>Arthritis and Rheumatism</i> , 2008, 59, 489-496.	6.7	32
255	Power doppler ultrasonographic monitoring of response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2008, 58, 2248-2256.	6.7	245
256	Cancer in Rheumatoid Arthritis: Occurrence, Mortality, and Associated Factors in a South European Population. <i>Seminars in Arthritis and Rheumatism</i> , 2008, 37, 388-397.	3.4	97
257	Adverse Reactions Related to the Administration of TNF Inhibitors. Analysis of a Registry of Biologic Therapy. <i>Reumatología Clínica (English Edition)</i> , 2008, 4, 90-95.	0.3	4
258	Trends towards improved disease state in Rheumatoid Arthritis over time: the influence of new therapies and changes in management approach: analysis of the EMECAR cohort. <i>Arthritis Research and Therapy</i> , 2008, 10, R138.	3.5	34
259	Prevalence of Paget's disease of bone in Spain. <i>Bone</i> , 2008, 43, 1006-1009.	2.9	38
260	The incidence of rheumatoid arthritis in Spain: results from a nationwide primary care registry. <i>Rheumatology</i> , 2008, 47, 1088-1092.	1.9	100
261	Burden of disease across chronic diseases: a health survey that measured prevalence, function, and quality of life. <i>Journal of Rheumatology</i> , 2008, 35, 159-65.	2.0	27
262	All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 880-885.	0.9	196
263	Disease pattern of spondyloarthropathies in Spain: description of the first national registry (REGISPONSER) extended report. <i>Rheumatology</i> , 2007, 46, 1309-1315.	1.9	160
264	Observed and expected frequency of comorbid chronic diseases in rheumatic patients. <i>Annals of the Rheumatic Diseases</i> , 2007, 67, 418-421.	0.9	30
265	Long-term experience of bosentan for treating ulcers and healed ulcers in systemic sclerosis patients. <i>Rheumatology</i> , 2007, 47, 464-466.	1.9	65
266	Longitudinal power Doppler ultrasonographic assessment of joint inflammatory activity in early rheumatoid arthritis: Predictive value in disease activity and radiologic progression. <i>Arthritis and Rheumatism</i> , 2007, 57, 116-124.	6.7	342
267	Musculoskeletal work disability for clinicians: Time course and effectiveness of a specialized intervention program by diagnosis. <i>Arthritis and Rheumatism</i> , 2007, 57, 335-342.	6.7	30
268	Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. <i>Arthritis and Rheumatism</i> , 2007, 57, 756-761.	6.7	378
269	How good is to switch between biologics? A systematic review of the literature. <i>Acta Reumatológica Portuguesa</i> , 2007, 32, 113-28.	0.2	9
270	Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER. <i>Arthritis Research and Therapy</i> , 2006, 8, R72.	3.5	167

#	ARTICLE	IF	CITATIONS
271	Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. <i>Arthritis Research and Therapy</i> , 2006, 8, R29.	3.5	250
272	Quantifying risks: The case between glucocorticoids and tuberculosis. <i>Arthritis and Rheumatism</i> , 2006, 55, 1-2.	6.7	5
273	Assessing utility values in rheumatoid arthritis: A comparison between time trade-off and the EuroQol. <i>Arthritis and Rheumatism</i> , 2006, 55, 751-756.	6.7	43
274	Survival, mortality and causes of death in inflammatory myopathies. <i>Autoimmunity</i> , 2006, 39, 205-215.	2.6	93
275	Recommendations to lower the risk of tuberculosis in patients treated with tumour necrosis factor alpha antagonists. <i>Acta Reumatológica Portuguesa</i> , 2006, 31, 201-3.	0.2	6
276	A Health System Program To Reduce Work Disability Related to Musculoskeletal Disorders. <i>Annals of Internal Medicine</i> , 2005, 143, 404.	3.9	46
277	Hormone replacement therapy for preventing cardiovascular disease in post-menopausal women. , 2005, , CD002229.		58
278	Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. <i>Arthritis and Rheumatism</i> , 2005, 52, 1766-1772.	6.7	612
279	Assessment of inflammatory activity in rheumatoid arthritis: a comparative study of clinical evaluation with grey scale and power Doppler ultrasonography. <i>Annals of the Rheumatic Diseases</i> , 2004, 64, 375-381.	0.9	379
280	Value of Disease Activity Score 28 (DAS28) and DAS28-3 compared to American College of Rheumatology-defined remission in rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2004, 31, 40-6.	2.0	87
281	Prevalence of silent amyloidosis in RA and its clinical significance. <i>Journal of Rheumatology</i> , 2004, 31, 1013-4; author reply 1014.	2.0	7
282	Costs and predictors of costs in rheumatoid arthritis: A prevalence-based study. <i>Arthritis and Rheumatism</i> , 2003, 49, 64-70.	6.7	155
283	Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active surveillance report. <i>Arthritis and Rheumatism</i> , 2003, 48, 2122-2127.	6.7	889
284	Rheumatoid arthritis in Spain: occurrence of extra-articular manifestations and estimates of disease severity. <i>Annals of the Rheumatic Diseases</i> , 2003, 62, 897-900.	0.9	194
285	Patterns of disease modifying antirheumatic drug use in a Spanish cohort of patients with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2003, 30, 697-704.	2.0	32
286	Increased risk of tuberculosis in patients with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2003, 30, 1436-9.	2.0	150
287	The prevalence of rheumatoid arthritis in the general population of Spain. <i>British Journal of Rheumatology</i> , 2002, 41, 88-95.	2.3	205
288	More evidence on the dysautonomic nature of fibromyalgia: The association with short stature. <i>Arthritis and Rheumatism</i> , 2002, 46, 1415-1416.	6.7	2

#	ARTICLE	IF	CITATIONS
289	The burden of musculoskeletal diseases in the general population of Spain: results from a national survey. <i>Annals of the Rheumatic Diseases</i> , 2001, 60, 1040-1045.	0.9	487
290	Predictors of rate of return to work after surgery for carpal tunnel syndrome. <i>Arthritis and Rheumatism</i> , 1998, 11, 298-305.	6.7	47
291	Reduction of Bone Mass in Women after Bone Marrow Transplantation. <i>Calcified Tissue International</i> , 1997, 60, 343-347.	3.1	63
292	Interleukin-1 inhibitors for chronic gout. <i>The Cochrane Library</i> , 0, , .	2.8	0